Market News & Trends
AMRI Launches Stand-Alone Service; Expanding Solutions for Impurity Analysis & Toxicology Risk Assessment
AMRI, a global contract research, development and manufacturing organization that partners with the pharmaceutical and biotechnology industries to improve patient outcomes and quality of life,…
Aptar Pharma Showcase its Premium Injectables Portfolio
Aptar Pharma, a leading drug delivery systems provider, will showcase the latest developments in its Premium injectables portfolio when it exhibits at Parenteral Drug Association’s…
eFFECTOR Initiates Dosing in Phase II Combination Trial
eFFECTOR Therapeutics, Inc. recently announced it has initiated dosing in a Phase 2 clinical study of eFT508 in combination with avelumab in microsatellite stable colorectal…
Recursion Pharmaceuticals Raises $60 Million to Industrialize Drug Discovery Using Artificial Intelligence
Recursion Pharmaceuticals, a biotechnology company that combines innovative biological science with artificial intelligence to discover new therapeutics at scale, is announcing its $60-million Series B…
OSE Immunotherapeutics Signs License Option Agreement
OSE Immunotherapeutics SA recently announced it has entered into an agreement with Inserm Transfert, on behalf of Inserm, a French public organization dedicated to human…
NANOBIOTIX Plans to Conduct First Clinical Trial
Nanobiotix recently announced its intention to start a new trial in the company's immuno-oncology (IO) program. The trial is aimed at expanding the potential of…
AIT Therapeutics Granted Orphan Drug Designation
AIT Therapeutics Inc. recently announced the US FDA has granted orphan drug designation to the company for its novel NO formulation for the treatment of…
Intra-Cellular Therapies Announces Enrollment of Clinical Trial
Intra-Cellular Therapies, Inc. recently announced the company has commenced enrollment in the ITI-214-105 Phase 1/2 clinical trial in patients with Parkinson’s disease (PD). “ITI-214 is…
KemPharm & Genco Sciences Announce Technology Licensing Agreement
KemPharm, Inc., a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, recently announced it has entered into a technology licensing…
Achieve Life Science Announces Advancement of Cytisine Clinical Development Program
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, recently announced the commencement of…
Amgen-Backed Immatics Lands $58 Million to Develop T-Cell Receptor-Based Immunotherapies
Immatics, a leading company in the field of cancer immunotherapy, recently announced the completion of its Series E financing, raising $58 million. The Series E…
ChromaDex Announces Top-line Results of its Second Human Clinical Trial
ChromaDex Corp. recently announced the initial results of its second human clinical study of NIAGEN nicotinamide riboside chloride (NR) have confirmed NR significantly and sustainably…
Amyris Enters Second Major Product Development & Production Agreement With Royal DSM
Amyris, Inc. recently announced it has entered into a product development and production agreement for Vitamin A with Koninklijke DSM N.V. (Royal DSM). This marks…
International Stem Cell Corporation to Expand its Revenue-Generating Biomedical Businesses to Support Ongoing & Future Clinical Trials
International Stem Cell Corporation recently announced that ISCO’s wholly owned subsidiaries Lifeline Cell Technology (LCT) and Lifeline Skin Care (LSC) expanded their manufacturing operations, OEM…
Aushon BioSystems & ABL, Inc. Announce Adoption of the Cira Platform
Aushon BioSystems and ABL, Inc. recently announced that ABL has adopted the Cira platform for multiplex and ultrasensitive biomarker analysis. Effective immediately, ABL will offer…
Intellia Therapeutics Demonstrates Sustained & Durable Genome Editing With CRISPR/Cas9 in 1-Year Animal Study
Intellia Therapeutics, Inc. recently presented the full 12-month data of its completed long-term mouse study, demonstrating robust and durable in vivo genome editing post single-dose,…
Ascendis Pharma Announces Dosing of Subjects in Phase 1 Trial
Ascendis Pharma A/S recently announced it has dosed subjects in a Phase 1 trial of TransCon PTH, a long-acting prodrug of parathyroid hormone (PTH) in…
American Heart Association's New Scientific Statement Deems the Corus CAD Test Valid & Useful for Clinicians Evaluating Obstructive CAD
CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, recently announced today in a Scientific Statement by the American Heart Association, the Corus® CAD…
Q BioMed Announces Development Partnership With Sphaera Pharma
Q BioMed Inc. recently announced a partnership with Sphaera Pharma to develop a new and proprietary analog of QBM-001 for pediatric developmental nonverbal disorder. "The…
ValGenesis Announces Strategic Partnership With VTI Life Sciences
ValGenesis Inc. recently announced the strategic partnership with VTI Life Sciences (VTI). This partnership enables VTI to provide clients with validation services using the latest…
